• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera…
New fund expands access to world-class mental health care for adolescents ages 12-17 HOUSTON, TX / ACCESS Newswire / December…
New fund expands access to world-class mental health care for adolescents ages 12-17 HOUSTON, TX / ACCESS Newswire / December…
December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”),…
Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company’s transition to the public markets and continued advancement of their…
MAULDIN, SC / ACCESS Newswire / December 18, 2025 / Management of Xcelerate, Inc. (OTCID:XCRT) today issued a year-end update…
MAULDIN, SC / ACCESS Newswire / December 18, 2025 / Management of Xcelerate, Inc. (OTCID:XCRT) today issued a year-end update…
A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to supportBUZZ…
A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to supportBUZZ…
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical…